[Use of pyridoxal phosphate and L-dopa in the treatment of cardiac insufficiency in patients with mitral defects and the active phase of rheumatism].
The effects of pyridoxal phosphate (PALP) and L-DOPA on the central hemodynamics and myocardial contractility were studied in 61 patients with associated heart insufficiency and active rheumatic fever. Introduction of PALP into a complex of treatment measures in a dose of 0.06 g a day for 21--24 days provides a more demonstrable effect than that of L-DOPA in a dose of 1.5 g a day for the same time. It is advisable to include PALP into a complex treatment of heart insufficiency in patients with associated mitral valve and active rheumatic fever.